AI Consensus Investment Thesis
JNJ: Johnson & Johnson Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Johnson & Johnson: 1-Year and 5-Year Forecast Outlook and Rating
Johnson & Johnson (JNJ) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $254 for , with -2.07% expected return (-0.80% including net dividends) and a PARTIAL SELL rating.
The 5-year target is $294 for , with +13.36% expected return (+21.51% including net dividends) and a NEUTRAL rating.
Latest available market price: USD 259, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.43%. As of 2026-10-20.
Gross TTM: 2.04% · Two-year annualized gross: 2%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 2.1% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Johnson & Johnson Flagship Insight
Valuation Reality Confronts Resilient Healthcare Cash Flow Compounding
There is high consensus that operational execution remains robust across oncology and cardiovascular intervention. However, sharp divergence persists regarding whether an elevated valuation multiple can withstand five percent Treasury yields, biosimilar margin erosion, and ongoing tort liabilities over the forward five-year investment horizon.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Elon Musk (Visionary)
Universal Investor (Polymath)
Machiavelli (Insider)
Michael Burry (Vulture)
Sherlock Holmes (Whistleblower)
Warren Buffett (Value Purist)
J.P. Morgan (Titan)
Superintelligence (Anthropologist)
Ray Dalio (Strategist)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Johnson & Johnson: forecast questions
What is Johnson & Johnson (JNJ)'s 1-year price forecast?
Johnson & Johnson's 1-year target is $254 for Sept 2027. The current AI rating is PARTIAL SELL. The expected return from the recorded close is -2.07%, or -0.80% modeled return including net dividends. Latest available market price: USD 259, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Johnson & Johnson (JNJ)'s 5-year price forecast?
Johnson & Johnson's 5-year target is $294 for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +13.36%, or +21.51% modeled return including net dividends. Latest available market price: USD 259, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 259, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Johnson & Johnson forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Johnson & Johnson differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Johnson & Johnson is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Johnson & Johnson: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Johnson & Johnson at the latest market close (20 Oct 2026): $12,151 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
* Return is calculated incl. 1.4% net dividend yield for Johnson & Johnson.
The base-case investment thesis resolves as an economic tug-of-war between durable business compounding and mechanical multiple compression. Operationally, the enterprise is successfully replacing legacy exclusivity losses through double-digit volume expansion in oncology anchors, newly approved targeted oral peptides, and high-barrier cardiovascular devices, supporting mid-single-digit top-line compounding toward $120 billion by 2031. However, starting valuations near 31x trailing earnings and an equity free cash flow yield below 3% create severe discount-rate vulnerability against persistent 5% risk-free sovereign benchmarks. As multiple normalization toward historical 18x to 20x parameters offsets underlying net income gains, capital appreciation will be muted, leaving dividends and share retirements to deliver the bulk of total shareholder returns.
Key insights
- Replacing expiring pharmaceutical exclusivity demands massive operational reinvestment, which dilutes incremental cash conversion even when reported adjusted earnings per share expand steadily.
- Policy frictions, specifically statutory Medicare price negotiations and expiring Section 232 tariff carve-outs in early 2029, place a structural ceiling on gross realizations.
- Portfolio optimization, including the planned orthopaedics separation, mechanically improves group growth and margin mix, yet cannot fully insulate equity multiples from macroeconomic yield competition.
Johnson & Johnson: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 259, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.43%. As of 2026-10-20.
Gross TTM: 2.04% · Two-year annualized gross: 2%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 2.1% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 270. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $262 | -2.92% | +1.02% | +1.25% | Elevated sovereign yields near five percent trigger institutional profit-taking in high-multiple defensive equities. Multiple compression outweighs solid quarterly operational volume, initiating a necessary valuation reset as flight-to-safety flows stabilize across broader asset markets. | $254 | $265 | $750 | |
| $256 | -2.25% | -1.30% | -0.72% | Full-year financial guidance confirms revenue crossing the hundred-billion milestone, but conservative outlooks highlight accelerating biosimilar erosion in legacy immunology. Slower forward net income compounding forces a downward recalibration of premium earnings multiples. | $244 | $273 | $736 | |
| $255 | -0.63% | -1.68% | -0.76% | Progress on claimant voting tallies for the proposed talc settlement reduces tail legal uncertainty, establishing fundamental valuation support. Commercial uptake of next-generation oncology biologics helps cushion residual generic discounting across European markets. | $244 | $278 | $743 | |
| $254 | -0.16% | -2.07% | -0.80% | Disposal or separation of the orthopaedics franchise clarifies the remaining portfolio profile and financing capacity. Stable cardiovascular procedure volumes balance initial settlement cash disbursements, keeping quarterly price performance tightly contained. | $237 | $270 | $755 | |
| $255 | +0.51% | -1.68% | -0.05% | Accelerating volume in subcutaneous oncology formulations and specialized catheter platforms lifts quarterly operating margins. Management's capital return commitments and disciplined buybacks reinforce price stability heading into the fiscal year-end close. | $229 | $280 | $776 | |
| $255 | -0.03% | -1.68% | +0.30% | Initial implementation of federally negotiated drug prices trims gross realizations on exposed biopharmaceutical lines. The market distinguishes top-line volume growth from retained operating cash margins, producing range-bound price action during quarterly consolidation. | $223 | $286 | $787 | |
| $259 | +1.59% | -0.14% | +2.24% | Positive clinical trial telemetry and expanding international regulatory clearances for interventional cardiovascular platforms support earnings expectations. Maturing launch infrastructure lowers incremental commercialization expenses, driving modest quarterly equity appreciation. | $218 | $295 | $803 | |
| $259 | 0.00% | -0.14% | +2.60% | Financing sensitivities among hospital procurement budgets temporarily moderate equipment placements. Nevertheless, non-discretionary procedural consumable demand and expanding hematology indications preserve robust underlying cash generation, limiting downside equity drift. | $216 | $289 | $812 | |
| $263 | +1.37% | +1.40% | +4.55% | The shrinking top-line weight of expired legacy biologics allows newer immunology launches to drive visible consolidated growth. Announcement of the sixty-sixth consecutive dividend raise provides reliable valuation support among conservative institutional income allocators. | $216 | $294 | $839 | |
| $262 | -0.43% | +1.02% | +4.52% | Expiration of Section 232 tariff carve-outs and statutory price caps introduce temporary margin headwinds. Sell-side models absorb these policy adjustments, prompting brief multiple digestion before operational mitigations take full effect. | $218 | $289 | $851 | |
| $266 | +1.60% | +2.56% | +6.50% | Domestic manufacturing optimizations absorb trade policy friction while high-margin cell therapy adoption expands globally. Demonstrating earnings durability amidst policy transitions rebuilds institutional confidence, generating measured upward share price momentum. | $220 | $295 | $872 | |
| $269 | +1.00% | +3.72% | +8.08% | Approaching composition-of-matter patent expirations on cornerstone oncology assets prompt proactive portfolio positioning. Market concerns are partially tempered by high patient retention on proprietary subcutaneous formulations and expanding robotic surgery adoption. | $218 | $297 | $886 | |
| $273 | +1.47% | +5.26% | +10.08% | Completion of multi-year biopharmaceutical supply-chain restructurings yields tangible manufacturing efficiencies. Annual free cash generation easily covers recurring capital commitments and opportunistic equity repurchases, lifting per-share valuation into year-end. | $220 | $306 | $910 | |
| $276 | +1.17% | +6.42% | +11.67% | Annual financial reporting showcases consolidated revenue expanding comfortably above historical thresholds with stable operating margins. Steady operational execution proves post-cliff resilience, prompting constructive earnings revisions across fundamental healthcare funds. | $225 | $309 | $916 | |
| $278 | +0.86% | +7.19% | +12.89% | Broadened international adoption of interventional cardiology devices and robotic surgical systems accelerates MedTech earnings compounding. Expanding high-margin procedural utilization insulates total cash flows from regional pharmaceutical price controls. | $227 | $310 | $937 | |
| $280 | +0.56% | +7.96% | +14.10% | Demographic aging trends across major developed economies sustain robust baseline volume growth for orthopedic and cardiovascular interventions. Highly predictable operating results support an orderly, low-volatility advance in the quoted equity value. | $227 | $313 | $947 | |
| $284 | +1.48% | +9.50% | +16.14% | Disciplined balance sheet redeployment through ongoing share cancellations and rising dividend payouts enhances total shareholder return. Deep commercial entrenchment across clinical hospital workflows reinforces the company's defensive competitive moat. | $229 | $318 | $970 | |
| $287 | +1.18% | +10.66% | +17.78% | Maturing commercial contributions from oral targeted peptides and next-generation bispecific antibodies establish unassailable therapeutic dominance. Sustainable mid-single-digit operating growth validates management's long-term portfolio regeneration strategy. | $231 | $324 | $980 | |
| $291 | +1.20% | +12.20% | +19.85% | Advanced automated manufacturing facilities lower per-unit biologic production costs, supporting operating profit margins near peak cycle levels. Steady cash conversion maintains robust liquidity, driving gradual equity appreciation toward fair value. | $234 | $331 | $1,000 | |
| $294 | +1.14% | +13.36% | +21.51% | The five-year transition cycle concludes with valuation multiples fully normalized near historical medians. High-quality operational earnings growth successfully absorbs past multiple compression, delivering stable capital preservation and reliable distributions. | $234 | $337 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Johnson & Johnson Stock Analysis & Scenarios Deep Dive
Johnson & Johnson: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Prevailing market sentiment treats the enterprise as an unassailable defensive sanctuary, bidding shares to over thirty times earnings following post-separation restructuring, strong oncology volume, and headline progress on a proposed $5.5 billion talc settlement. This consensus relies on the assumption that non-cyclical healthcare demand and $100 billion in revenue insulate the stock from interest rate gravity, complacently treating rich valuation multiples as permanent.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially overestimates valuation durability, creating measurable stock overpricing. The market's blind spot is treating defensive pharmaceutical stability as immune to capital-market discount rates when benchmark Treasuries yield near five percent. Crucially, investors overlook that replacing expiring high-margin biologic rents requires heavy ongoing commercialization expenditure and absorbs statutory price concessions, meaning mid-single-digit operational growth cannot sustain premium multiples once safe-haven flight flows unwind.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst is the disclosure of full-year financial guidance bridges revealing margin dilution from biosimilar discounting and statutory Medicare price concessions, paired with actual settlement cash disbursements. Over the next two to six quarters, institutional allocators comparing mid-single-digit earnings expansion against five percent risk-free sovereign alternatives will rebalance capital out of crowded defensive equities, compelling multiple mean reversion toward historical conglomerate norms.
Johnson & Johnson: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Greed
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Overshoot
While reports unanimously agree that defensive crowding has produced a valuation overshoot, they diverge on whether multiple deflation will cause an immediate nominal drawdown or be absorbed gradually through steady multi-year operational earnings compounding.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regime of sticky inflation, policy rates near four percent, and ten-year Treasury yields near five percent constitutes a decisive valuation headwind. While inelastic somatic healthcare demand completely insulates patient volume from macroeconomic cyclicality, the company's thin free cash flow yield leaves equity valuation acutely exposed to discount-rate competition from sovereign debt.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive debate centers on valuation elasticity versus operational durability. One perspective argues that paying 31x trailing earnings for a five percent revenue grower during a five percent Treasury regime guarantees severe capital destruction as multiples mean-revert. The opposing thesis contends that superior oncology execution, cardiovascular device integration, and litigation ring-fencing justify a durable scarcity premium that cushions the multiple. Resolving this disagreement requires observing full-year 2027 gross margin realizations and checking whether organic sales growth exceeds six percent as Stelara biosimilar discounts accelerate.
Johnson & Johnson: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Oncology and hematology franchise expansion | Innovation And Product | +18% | +24% | Commercial scaling of Darzalex, including rapid conversion to subcutaneous Faspro formulations, combined with earlier-line adoption of Carvykti cell therapy and bispecific antibodies, secures dominant market share in hematologic malignancies. This clinical execution generates durable, high-margin biologic cash flows exceeding $22 billion annually, successfully backfilling off-patent revenue voids. |
| Cardiovascular MedTech integration synergies | Competitive Positioning | +13% | +16% | Strategic integration of Shockwave Medical and Abiomed into the global electrophysiology infrastructure establishes commanding chokepoints in intravascular lithotripsy and mechanical circulatory support. High procedural switching costs and non-deferrable clinical interventions protect segment gross margins above 70%, accelerating MedTech organic top-line contributions toward seven percent annually. |
| Talc litigation liability ring fencing | Regulatory | +11% | +6.0% | Advancing a consensual $5.5 billion settlement covering approximately 76,000 ovarian cancer claimants systematically transforms open-ended tort liabilities into predictable, amortized cash disbursements. Achieving final judicial confirmation eliminates an existential institutional governance discount, releasing restricted balance-sheet reserves and restoring long-term credit stability without imperiling ongoing operations. |
| Fortress balance sheet capital compounding | Capital Allocation | +9.0% | +10% | Armed with a pristine AAA credit profile and annual free cash flow exceeding $19 billion, management executes disciplined capital allocation. Consistent dividend increases spanning over six decades paired with programmatic share repurchases retiring roughly one percent of float annually systematically cushion per-share intrinsic value through restrictive credit cycles. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Valuation multiple mean reversion drag | Macroeconomic And Macrofinancial | -20% | -1.0% | Trading at an anomalous multiple above 31x trailing earnings with a sub-3% free cash flow yield creates an unsustainable spread against 5% sovereign Treasury yields. As defensive safe-haven crowding subsides, mechanical multiple mean reversion toward historical 18x to 20x parameters exerts severe downward pressure on quoted equity prices. |
| Stelara biosimilar patent cliff erosion | Competitive Positioning | -13% | -15% | Accelerating biosimilar penetration against cornerstone immunology biologic Stelara across North American and European formularies strips billions in high-margin cash flow. Price discounts exceeding forty percent create an ongoing top-line operational drag that newer pipeline assets must expend substantial commercial capital to replace. |
| Statutory drug price negotiation mandates | Regulatory | -10% | -11% | Federal price negotiation frameworks under the Inflation Reduction Act enforce statutory discounts across major biopharma therapies, including upcoming cycles affecting key cardiovascular and oncology treatments. These mandatory concessions compress domestic gross-to-net realizations, placing an unyielding structural ceiling on pharmaceutical operating margin expansion. |
| Trade policy and tariff expiry | Political And Geopolitical | -8.0% | -7.0% | Proclamation 11020 pharmaceutical tariff exemptions tied to onshoring and most-favored-nation pricing agreements carry a firm expiration date on January 20, 2029. The approaching expiration threatens import duty reversions while enforced international reference pricing structurally erodes net realizations across core biopharmaceutical franchises. |
Johnson & Johnson: What Could Break or Accelerate the Thesis
Event Risk Score: Moderate 40/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Talc settlement collapse and litigation | 30% | -21% | Claimant balloting failing to achieve the mandatory 95% threshold would void the proposed $5.5 billion settlement, remanding tens of thousands of active tort claims back to state jury dockets. Exposure to runaway punitive verdicts exceeding billions in single awards would force emergency litigation reserve additions, impairing net earnings and triggering severe multiple de-rating. |
| Commercial price control legislative expansion | 22% | -19% | Bipartisan federal legislation expanding mandatory statutory price negotiation caps from Medicare into private employer commercial insurance formularies would permanently dismantle domestic biopharma gross realizations. Slicing billions directly from core oncology and immunology revenues would structurally reduce return on invested capital and induce violent equity derating. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Oral immunology peptide market sweep | 32% | +19% | Pivotal Phase 3 readouts and regulatory label expansions establishing oral IL-23 inhibitor icotrokinra as first-line therapy across inflammatory bowel diseases would transform autoimmune treatment paradigms. Dislodging injectable biologics with shelf-stable oral convenience would expand addressable patient volume threefold, unlocking over $8 billion in peak annual sales and driving substantial operating margin accretion. |
| Ottava surgical robotics commercial ascendancy | 28% | +15% | Securing rapid commercial hospital network standardization for the Ottava soft-tissue robotic platform would break entrenched incumbent surgical monopolies. Capitalizing on Ethicon's vast hospital footprint to drive recurring proprietary instrument and digital consumable sales would accelerate MedTech division growth into double digits, triggering broad institutional multiple expansion across the enterprise. |
Company Financial AnalysisJohnson & Johnson: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Johnson & Johnson financials here.
Earnings and financials
The enterprise is demonstrating genuine top-line resilience, with annual revenues surpassing the milestone of one hundred billion dollars behind robust volume growth in flagship oncology medicines and cardiovascular devices. These expanding franchises have effectively absorbed the steep revenue drop in older blockbuster treatments like Stelara following the arrival of low-cost biosimilars. However, reported headline profits continue to be distorted by volatile legal reserves and acquisition amortizations. Beneath these accounting swings, underlying owner earnings are compounding at a stable mid-single-digit pace, backed by around twenty-two billion dollars in reconstructed trailing free cash flow that provides solid foundation for operations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 94.2B | USD 26.8B | USD 19.7B |
| 2024 | USD 88.8B | USD 14.1B | USD 19.8B |
| 2023 | USD 85.2B | USD 35.2B | USD 18.2B |
| 2022 | USD 80B | USD 17.9B | USD 17.2B |
| 2021 | USD 78.7B | USD 20.9B | USD 19.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.8x | TTM | Native | USD / USD |
| 2024 | 25.0x | TTM | Native | USD / USD |
| 2023 | 10.8x | TTM | Native | USD / USD |
| 2022 | 26.2x | Annual | Native | USD / USD |
| 2021 | 21.9x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Operating margins have shown healthy resilience near twenty-seven percent, supported by corporate streamlining following the consumer health spin-off and favorable product mix toward high-margin cancer therapies. Disciplined administrative cost control has helped protect overall profitability despite persistent inflation in hospital labor and specialized supply chains. Looking ahead, maintaining gross margins near sixty-eight percent will become increasingly challenging. Severe biosimilar price discounting on legacy treatments alongside mandatory government Medicare price caps represent structural headwinds that sales volume gains can only partially offset, keeping a tight ceiling on further profit margin expansion.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 25.6B | 27.2% | 28.5% |
| 2024 | USD 22.1B | 24.9% | 15.8% |
| 2023 | USD 21.9B | 25.7% | 41.3% |
| 2022 | USD 21B | 26.3% | 22.4% |
| 2021 | USD 20.9B | 26.6% | 26.5% |
Balance sheet and leverage
The enterprise preserves an elite AAA-rated balance sheet characterized by conservative financial leverage, a debt-to-equity ratio of 0.59, and interest coverage exceeding thirty-four times operating earnings. This pristine solvency profile allows management to easily absorb major acquisitions and maintain debt service without facing credit market stress. Nevertheless, significant resources are already earmarked for pending legal commitments. While the proposed five-point-five billion dollar talc settlement is well within the company's annual free cash flow capacity, funding these multi-year payouts and potential tariff-related onshoring investments will temporarily limit excess cash available for aggressive share repurchases.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 47.9B | USD 20.1B | USD 28.2B net debt | USD 27.8B | 1.03x |
| 2024 | USD 36.6B | USD 24.5B | USD 12.5B net debt | USD 12.1B | 1.11x |
| 2023 | USD 29.3B | USD 22.9B | USD 7.5B net debt | USD 6.4B | 1.16x |
| 2022 | USD 39.6B | USD 22.3B | USD 26.8B net debt | USD 17.4B | 0.99x |
| 2021 | USD 33.8B | USD 31.6B | USD 19.3B net debt | USD 2.1B | 1.35x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management maintains disciplined capital spending, directing roughly five percent of annual revenue into modernizing advanced biologic production facilities and precision medical device plants. Rather than overspending on excess physical factories, capital deployment has deliberately prioritized targeted external acquisitions like Shockwave Medical to secure proven, high-margin technologies. This capital allocation posture allows the company to replace expiring patent revenue without overextending its operational budget. The company's multi-billion-dollar domestic investment commitments focus on high-return cell therapies and surgical robotics, which should generate reliable long-term cash flow while safeguarding overall returns on invested capital.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 4.8B | USD 14.7B |
| 2024 | USD 4.4B | USD 17.2B |
| 2023 | USD 4.5B | USD 15B |
| 2022 | USD 4B | USD 14.1B |
| 2021 | USD 3.7B | USD 14.3B |
Behind the synthesisJohnson & Johnson: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The common causal pattern across all submissions is that commercial operations are expanding at five to six percent annually, driven by oncology volume and cardiovascular MedTech integration, but face an acute multiple compression headwind. An elevated trailing price-to-earnings ratio and a thin free cash flow yield leave the asset vulnerable to capital reallocation when risk-free sovereign yields approach five percent. Submissions with the highest evidentiary quality meticulously reconcile official cash conversion, separate biosimilar replacement revenue from incremental earnings, and incorporate verified policy timelines, including statutory Medicare negotiations and Section 232 tariff carve-outs expiring in early 2029. Lower weights are assigned to reports that rely on rhetorical assertions or project catastrophic derating without accounting for pristine balance-sheet flexibility and steady share retirements. The strongest credible contrarian insight confirms that defensive scarcity has driven an equity multiple overshoot that requires multi-year earnings compounding to digest.
All 14 opinions
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 13.5%
Highest evidentiary rigor among the submissions, verifying official SEC filings, reconciling trailing free cash flows, and incorporating specific regulatory approvals like the targeted oral peptide. Carefully separates replacement revenue from incremental growth.
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 11.5%
Exceptional evidentiary quality incorporating granular primary documentation on Section 232 tariff carve-outs, DePuy divestiture pathways, and talc settlement structures. The causal chain connecting policy expiries to net realized price erosion is highly persuasive.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 9.6%
Offers forensic scrutiny of GAAP versus non-GAAP reconciliations, litigation contingency accounting, and subcutaneous formulation defenses against biosimilar entry. Grounds intermediate price targets in audited financial milestones and concrete clinical launch timelines.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.7%
Presents rigorous economic reasoning regarding terminal cash flow replacement and the drag of elevated Treasury yields against thin equity risk premia. Balances operational pipeline scale across hematology with legitimate multiple compression risks over the forecast horizon.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.7%
Constructs a balanced view of cardiovascular MedTech integration offsetting patent expirations. Clearly articulates the negative equity risk premium while appropriately modeling moderate recovery as newer oncology and immunology assets reach commercial maturity.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.7%
Delivers an incisive forensic dissection of unhedged state-level tort exposure and multiple mean reversion. Offers essential downside risk modeling, though its projection of persistent net multiple deflation discounts management's demonstrated ability to convert operating earnings.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.7%
Provides strong institutional analysis of commercial scale, predatory balance sheet deployment, and hospital switching costs. While appropriately cautious on near-term rate headwinds, it builds a well-reasoned operational compounding scenario through 2031.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.7%
Strong analytical focus on procurement power, statutory Medicare negotiation dynamics, and institutional capital flows. Effectively demonstrates how operational gains can be neutralized by regulatory price friction over a multi-year forecast horizon.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.8%
Effectively models macro discount rate transmission onto equity multiples in a restrictive monetary regime. While its debt-cycle framing is sound, it somewhat underestimates operating margin leverage from post-separation cost rationalization.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.8%
Provides a disciplined owner-earnings framework contrasting six percent organic compounding against elevated starting valuations. The analysis is causally sound but relies on standard valuation heuristics without exploring specific regulatory tariff mechanics.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.8%
Detailed evaluation of gross margin degradation resulting from biosimilar penetration and hospital budgeting caps. Well-structured economically, though its path assumes prolonged multiple stagnation that underweights pipeline commercialization upside.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.8%
This analysis provides a useful critique of multiple vulnerability and patent cliff dynamics. However, its assumption of an unmitigated valuation collapse to seventeen times earnings understates the cash cushion provided by recent oncology and cardiovascular acquisitions.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.8%
Correctly highlights the disconnect between a sub-three percent free cash flow yield and prevailing Treasury rates. However, its path models a severe initial price decline that slightly overstates biosimilar margin destruction.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.8%
Presents a forceful contrarian case on defensive crowding and bond-proxy mispricing. While its behavioral insights are compelling, the projected price trajectory relies on extreme multiples de-rating that discounts balance-sheet cash deployment.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Johnson & Johnson forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web36 available sources from this batch (119 recorded). The first 15 are shown below; expand to read the rest.
- CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation | CMS cms.gov
- https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/a2026q1exhibit993.htm?utm_source=openai sec.gov
- jnj-20260628 sec.gov
- Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation jnj.com
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook jnj.com
- Johnson & Johnson Is Near a Record High. Is There Still Room to Run? - 24/7 Wall St. 247wallst.com
- Trump Administration Announces Section 232 Tariffs on Pharmaceuticals | Brownstein bhfs.com
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook - BioSpace biospace.com
- U.S. Pharma Tariffs And MFN Become Law After April 2 Update clinicalleader.com
- J&J to spin off orthopedics business, sees 2026 sales growth of over 5% cnbc.com
- JNJ Stock Quote Price and Forecast | CNN cnn.com
- Talcum Powder Settlement | $5.5 Billion Johnson & Johnson Offer consumernotice.org
- A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insights dcatvci.org
- Johnson & Johnson Talcum Powder Lawsuit [August 2026 ] drugwatch.com
- J&J move to spin off orthopedics unit is 'all about shrinking to grow faster,' exec says fiercebiotech.com
Show 21 more sources
- J&J to spin off orthopedics business, sees 2026 sales growth of over 5% finance.yahoo.com
- Johnson & Johnson Is Near a Record High. Is There Still Room to Run? finance.yahoo.com
- Executive Order Imposing Section 232 Tariffs on Pharmaceuticals and Pharmaceutical Ingredients | Foley Hoag LLP foleyhoag.com
- Johnson & Johnson stock is busting out to new highs; is there more upside? By Investing.com investing.com
- FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide | Johnson & Johnson investor.jnj.com
- ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis | Johnson & Johnson investor.jnj.com
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook | Johnson & Johnson investor.jnj.com
- Corporate press releases | Johnson & Johnson jnj.com
- Financial press releases | Johnson & Johnson jnj.com
- https://www.jnj.com/download/johnson-johnson-2025-annual-report jnj.com
- Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System jnj.com
- Johnson & Johnson reports Q4 and Full-Year 2025 results jnj.com
- Talcum Powder Lawsuit Update | 2026 Status & Settlements lawfirm.com
- Talc Baby Powder Lawsuit | September 2026 Update lawsuit-information-center.com
- Johnson & Johnson - 15 Year Stock Price History | JNJ | MacroTrends macrotrends.net
- J&J DePuy Synthes Sale: Orthopedics Divestiture and MedTech Spinoff Guide | MedDeviceGuide meddeviceguide.com
- Johnson & Johnson (JNJ) Investor Relations, Earnings Summary & Outlook quartr.com
- Q4 2025 Johnson & Johnson Earnings Call on January 21, 2026 / 1:30PM s203.q4cdn.com
- Deadline Approaching for Companies Seeking Onshoring Deals to Reduce Section 232 Pharmaceutical Tariffs | Skadden, Arps, Slate, Meagher & Flom LLP skadden.com
- Talcum Powder Litigation Update 2026 sokolovelaw.com
- J&J Stock: Analysis, Forecast & Dividend 2026 - Dividends Paradise🚀 steady.page
83 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.